427 related articles for article (PubMed ID: 20388847)
21. mTORC1 inhibitors rapamycin and metformin affect cardiovascular markers differentially in ZDF rats.
Nistala R; Raja A; Pulakat L
Can J Physiol Pharmacol; 2017 Mar; 95(3):281-287. PubMed ID: 28177677
[TBL] [Abstract][Full Text] [Related]
22. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells.
Xie Y; Wang YL; Yu L; Hu Q; Ji L; Zhang Y; Liao QP
J Steroid Biochem Mol Biol; 2011 Sep; 126(3-5):113-20. PubMed ID: 21168492
[TBL] [Abstract][Full Text] [Related]
23. Metformin and Breast Cancer: Molecular Targets.
Faria J; Negalha G; Azevedo A; Martel F
J Mammary Gland Biol Neoplasia; 2019 Jun; 24(2):111-123. PubMed ID: 30903363
[TBL] [Abstract][Full Text] [Related]
24. Insulin potentiates Ca2+ signaling and phosphatidylinositol 4,5-bisphosphate hydrolysis induced by Gq protein-coupled receptor agonists through an mTOR-dependent pathway.
Kisfalvi K; Rey O; Young SH; Sinnett-Smith J; Rozengurt E
Endocrinology; 2007 Jul; 148(7):3246-57. PubMed ID: 17379645
[TBL] [Abstract][Full Text] [Related]
25. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.
Tamburini J; Chapuis N; Bardet V; Park S; Sujobert P; Willems L; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
Blood; 2008 Jan; 111(1):379-82. PubMed ID: 17878402
[TBL] [Abstract][Full Text] [Related]
26. Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
Ben Sahra I; Le Marchand-Brustel Y; Tanti JF; Bost F
Mol Cancer Ther; 2010 May; 9(5):1092-9. PubMed ID: 20442309
[TBL] [Abstract][Full Text] [Related]
27. Metformin in selected malignancies in women.
Markowska A; Stanislawiak-Rudowicz J; Kasprzak T; Markowska J; Szarszewska M
Ginekol Pol; 2022; 93(5):416-421. PubMed ID: 35072253
[TBL] [Abstract][Full Text] [Related]
28. Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex.
Howell JJ; Hellberg K; Turner M; Talbott G; Kolar MJ; Ross DS; Hoxhaj G; Saghatelian A; Shaw RJ; Manning BD
Cell Metab; 2017 Feb; 25(2):463-471. PubMed ID: 28089566
[TBL] [Abstract][Full Text] [Related]
29. Curcumin disrupts the Mammalian target of rapamycin-raptor complex.
Beevers CS; Chen L; Liu L; Luo Y; Webster NJ; Huang S
Cancer Res; 2009 Feb; 69(3):1000-8. PubMed ID: 19176385
[TBL] [Abstract][Full Text] [Related]
30. Prostaglandin E2 activates the mTORC1 pathway through an EP4/cAMP/PKA- and EP1/Ca2+-mediated mechanism in the human pancreatic carcinoma cell line PANC-1.
Chang HH; Young SH; Sinnett-Smith J; Chou CE; Moro A; Hertzer KM; Hines OJ; Rozengurt E; Eibl G
Am J Physiol Cell Physiol; 2015 Nov; 309(10):C639-49. PubMed ID: 26310818
[TBL] [Abstract][Full Text] [Related]
31. Metformin sensitizes insulin signaling through AMPK-mediated PTEN down-regulation in preadipocyte 3T3-L1 cells.
Lee SK; Lee JO; Kim JH; Kim SJ; You GY; Moon JW; Jung JH; Park SH; Uhm KO; Park JM; Suh PG; Kim HS
J Cell Biochem; 2011 May; 112(5):1259-67. PubMed ID: 21465524
[TBL] [Abstract][Full Text] [Related]
32. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy.
van der Veeken J; Oliveira S; Schiffelers RM; Storm G; van Bergen En Henegouwen PM; Roovers RC
Curr Cancer Drug Targets; 2009 Sep; 9(6):748-60. PubMed ID: 19754359
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of midkine by metformin can contribute to its anticancer effects in malignancies: A proposal mechanism of action of metformin in context of endometrial cancer prevention and therapy.
Karadeniz Z; Aynacıoğlu AŞ; Bilir A; Tuna MY
Med Hypotheses; 2020 Jan; 134():109420. PubMed ID: 31634770
[TBL] [Abstract][Full Text] [Related]
34. Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma.
Zhou G; Yu J; Wang A; Liu SH; Sinnett-Smith J; Wu J; Sanchez R; Nemunaitis J; Ricordi C; Rozengurt E; Brunicardi FC
Curr Mol Med; 2016; 16(1):83-90. PubMed ID: 26695692
[TBL] [Abstract][Full Text] [Related]
35. Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study.
Dowling RJ; Niraula S; Chang MC; Done SJ; Ennis M; McCready DR; Leong WL; Escallon JM; Reedijk M; Goodwin PJ; Stambolic V
Breast Cancer Res; 2015 Mar; 17(1):32. PubMed ID: 25849721
[TBL] [Abstract][Full Text] [Related]
36. Metformin as an Anticancer Agent.
Vancura A; Bu P; Bhagwat M; Zeng J; Vancurova I
Trends Pharmacol Sci; 2018 Oct; 39(10):867-878. PubMed ID: 30150001
[TBL] [Abstract][Full Text] [Related]
37. The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells in vitro and in vivo.
Zhang T; Guo P; Zhang Y; Xiong H; Yu X; Xu S; Wang X; He D; Jin X
Int J Mol Sci; 2013 Dec; 14(12):24603-18. PubMed ID: 24351837
[TBL] [Abstract][Full Text] [Related]
38. Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning.
Gadducci A; Biglia N; Tana R; Cosio S; Gallo M
Crit Rev Oncol Hematol; 2016 Sep; 105():73-83. PubMed ID: 27378194
[TBL] [Abstract][Full Text] [Related]
39. Interaction of glibenclamide and metformin at the level of translation in pancreatic β cells.
Wang Q; Cai Y; Van de Casteele M; Pipeleers D; Ling Z
J Endocrinol; 2011 Feb; 208(2):161-9. PubMed ID: 21084384
[TBL] [Abstract][Full Text] [Related]
40. Hypoxia Increases IGFBP-1 Phosphorylation Mediated by mTOR Inhibition.
Damerill I; Biggar KK; Abu Shehab M; Li SS; Jansson T; Gupta MB
Mol Endocrinol; 2016 Feb; 30(2):201-16. PubMed ID: 26714229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
